比较两种不同mRNA-based COVID-19疫苗作为第四剂的免疫原性和疗效六个月后续行动，以色列，2021年12月27日至2022年7月24日。

IF 7.8

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin Pub Date : 2022-09-01 DOI:10.2807/1560-7917.ES.2022.27.39.2200701

Noam Barda, Michal Canetti, Mayan Gilboa, Victoria Indenboim, Keren Asraf, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zibly, Ram Doolman, Ella Mendelson, Dror Harats, Laurence S Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay

{"title":"比较两种不同mRNA-based COVID-19疫苗作为第四剂的免疫原性和疗效六个月后续行动，以色列，2021年12月27日至2022年7月24日。","authors":"Noam Barda, Michal Canetti, Mayan Gilboa, Victoria Indenboim, Keren Asraf, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zibly, Ram Doolman, Ella Mendelson, Dror Harats, Laurence S Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay","doi":"10.2807/1560-7917.ES.2022.27.39.2200701","DOIUrl":null,"url":null,"abstract":"We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98-1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.","PeriodicalId":520613,"journal":{"name":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","volume":" ","pages":""},"PeriodicalIF":7.8000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524052/pdf/","citationCount":"4","resultStr":"{\"title\":\"Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022.\",\"authors\":\"Noam Barda, Michal Canetti, Mayan Gilboa, Victoria Indenboim, Keren Asraf, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zibly, Ram Doolman, Ella Mendelson, Dror Harats, Laurence S Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay\",\"doi\":\"10.2807/1560-7917.ES.2022.27.39.2200701\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98-1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.\",\"PeriodicalId\":520613,\"journal\":{\"name\":\"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524052/pdf/\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

摘要

我们评估了Spikevax和Comirnaty作为第四剂COVID-19疫苗的免疫原性和有效性。第四次接种后6个月，Spikevax疫苗的IgG水平比第四次接种前高1.58倍(95% CI: 1.27-1.97)， community疫苗的IgG水平比第四次接种前高1.16倍(95% CI: 0.98-1.37)。近60%(159/274)的疫苗接种者感染了SARS-CoV-2。Spikevax的感染风险比(hr)为0.82;95% CI: 0.62-1.09)和共伴性(0.86;95% CI: 0.65-1.13)疫苗接种者相似，实质疾病hr也相似，分别为0.28 (95% CI: 0.13-0.62)和0.51 (95% CI: 0.27-0.96)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022.

查看原文本刊更多论文

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022.

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98-1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

自引率

0.00%

发文量